0000000000544572

AUTHOR

Janice Pogue

showing 2 related works from this author

Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction…

2006

Background— Individual markers of inflammation may add incremental predictive value in the context of conventionally available risk factors. We evaluated the ability of 9 inflammatory biomarkers, microalbuminuria, and N-terminal pro-brain natriuretic peptide (Nt-proBNP) to improve cardiovascular risk prediction beyond that obtained from traditional risk factors in a secondary-prevention population. Methods and Results— We measured biomarkers representing the acute-phase reaction (C-reactive protein, fibrinogen, and interleukin-6), proinflammatory pathways (soluble tumor necrosis factor receptor-1 and -2, soluble interleukin-1 receptor antagonist, and interleukin-18), endothelial activation…

MaleOncologymedicine.medical_specialtyHeart Diseasesmedicine.drug_classPopulationMyocardial InfarctionAngiotensin-Converting Enzyme InhibitorsContext (language use)Coronary Artery DiseaseProinflammatory cytokineEndothelial activationRamiprilPredictive Value of TestsRisk FactorsPhysiology (medical)Internal medicineNatriuretic Peptide BrainNatriuretic peptideHumansVitamin EMedicineRisk factoreducationAgededucation.field_of_studyInterleukin-6business.industryFibrinogenMiddle Agedmedicine.diseaseBrain natriuretic peptideC-Reactive ProteinEndocrinologyFemaleMicroalbuminuriaCardiology and Cardiovascular MedicinebusinessBiomarkers
researchProduct

Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpo…

2009

Hypertension guidelines advise aggressive blood pressure (BP) lowering in patients with diabetes or high cardiovascular risk, but supporting evidence is limited. We analysed the impact of BP on cardiovascular events in well treated high-risk patients enrolled in a large clinical trial (Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Twenty-five thousand five hundred and eighty-eight patients with atherosclerotic disease or diabetes with organ damage, tolerant to angiotensin-converting enzyme inhibitors, were randomized to ramipril, telmisartan or both. We related the primary composite outcome and its components to: baseline SBP; SBP changes from baseline to…

RamiprilMalemedicine.medical_specialtyPhysiologyAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineInternal MedicinemedicineHumansTelmisartanRisk factorAntihypertensive AgentsAgedVascular diseasebusiness.industryMiddle Agedmedicine.diseasePrognosisAngiotensin IISurgeryClinical trialBlood pressureTreatment OutcomeHypertensionCardiologyBenzimidazolesFemaleTelmisartanCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of hypertension
researchProduct